Published 10 days ago • loading... • Updated 10 days ago

Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer

On Tuesday, May 19, 2026, Houston-based Delphi Diagnostics announced the appointment of Eric Lindquist as Chief Financial Officer, effective April 1, 2026, to lead financial strategy and support the company's next phase of growth.
Lindquist brings decades of leadership experience from pharmaceutical and diagnostics companies, having previously served as Chief Executive Officer of InnoSIGN, where he led strategic transformations and completed multiple financing rounds.
Delphi is advancing its Endocrine Activity Index test, a diagnostic tool developed at the University of Texas MD Anderson Cancer Center to predict chemotherapy response in stage II-III breast cancer patients.
Previously, Lindquist held roles at Celcuity and Natera, where he contributed to launching the Signatera test and helped establish Roche as a leader in companion diagnostics through strategic partnerships.
Delphi aims to expand access to the EAI test for breast cancer patients, positioning the company to open new pathways for personalized treatment while supporting its next phase of commercial growth under Lindquist's financial leadership.

Insights by Ground AI